Herman Feringa
Cardiovascular Disease · Palmer, AKNPI 1356597827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $350 and has fallen 94.6% since, to $19 in 2025.
Across 49 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$144
- E.r. Squibb & Sons, L.L.C.$133
- Shockwave Medical, Inc$120
- Astellas Pharma US Inc$99
- Amgen$95
- Pfizer$82
- plus $447 from 13 others
What the payments were for
- Food & beverage$1,02091%
- Education$999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $144 |
| E.r. Squibb & Sons, L.L.C. | 7 | $133 |
| Shockwave Medical, Inc | 2 | $120 |
| Astellas Pharma US Inc | 1 | $99 |
| Amgen | 5 | $95 |
| Pfizer | 3 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| Abbott | 1 | $78 |
| Boehringer Ingelheim | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 3 | $42 |
| Johnson & Johnson | 2 | $35 |
| AstraZeneca | 2 | $33 |
| Merck | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Bayer | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$1,119 in reported general payments places this provider in the 55th percentile of 26 cardiovascular disease providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 279 | $385,968 |
| EntrestoSacubitril/Valsartan | 107 | $131,153 |
| XareltoRivaroxaban | 34 | $45,238 |
| Repatha SureclickEvolocumab | 30 | $33,560 |
| JardianceEmpagliflozin | 27 | $28,909 |
| Metoprolol Succinate | 469 | $8,038 |
| Rosuvastatin Calcium | 356 | $7,080 |
| Atorvastatin Calcium | 331 | $4,411 |
| Ezetimibe | 103 | $3,238 |
| Losartan Potassium | 272 | $2,976 |
| Nebivolol Hcl | 25 | $2,701 |
| Omega-3 Acid Ethyl Esters | 12 | $2,467 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 15 | $2,099 |
| ClopidogrelClopidogrel Bisulfate | 152 | $1,781 |
| Ranolazine ErRanolazine | 14 | $1,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $385,968279 claims |
| NovartisEntresto | $144 | $131,153107 claims |
| Johnson & JohnsonXarelto | $35 | $45,23834 claims |
| Boehringer IngelheimJardiance | $48 | $28,90927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 26 cardiovascular disease providers in Alaska.
Other cardiovascular disease in Palmer
- Suneet PurohitAnchorage$77K
- Ahmed AbuzaidAnchorage$77K
- Danielle VeronneauJber$10K
- Hanna KonarzewskaFairbanks$5K
- Jeffrey DixsonAnchorage$2K
- Brian ScullyAnchorage$2K
- Mario BinderAnchorage$2K
- David StieberFairbanks$2K
- Hung VoAnchorage$1K
- William MayerAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.